Related Experiment Video

Updated: Mar 19, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma

C A VON Klot1, Axel S Merseburger2, Markus A Kuczyk1

  • 1Department of Urology and Urological Oncology, Hannover University Medical School, D-30625 Hannover, Germany.

Molecular and Clinical Oncology
|June 18, 2016
PubMed

Insights

New targeted therapies, nivolumab and cabozantinib, offer improved second-line treatment options for metastatic renal cell carcinoma (mRCC). These advancements provide hope for patients with advanced kidney cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has evolved significantly since 2007 with targeted therapies.
  • Previous therapies primarily focused on vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) pathways.

Purpose of the Study:

  • To review the current landscape of second-line therapy for mRCC.
  • To discuss the efficacy of recently approved agents, nivolumab and cabozantinib.

Main Methods:

  • Review of recent randomized controlled trials, including CheckMate-25 and METEOR.
  • Analysis of clinical data for nivolumab and cabozantinib in the second-line setting for mRCC.

Main Results:

  • Nivolumab demonstrated significant improvements in overall survival in the CheckMate-25 trial.
  • Cabozantinib showed superior progression-free survival and overall survival in the METEOR trial compared to everolimus.
  • Both agents represent important advancements in second-line mRCC treatment.

Conclusions:

  • Nivolumab and cabozantinib are effective second-line treatment options for patients with mRCC.
  • These agents expand therapeutic choices and improve outcomes for patients progressing on first-line therapy.
  • Further research is ongoing to optimize sequencing and combination strategies.
Keywords:
cabozantinibnivolumabrapamycinrenal cell carcinomavascular endothelial growth factor

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K